Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Clopidogrel pretreatment is recommended for patients undergoing percutaneous coronary intervention (PCI).
• Evidence linking clopidogrel pretreatment to improved clinical outcomes after PCI remains inconclusive.

Purpose of the Study:

• To evaluate the association between clopidogrel pretreatment and mortality and major bleeding following PCI.
• To assess the impact of clopidogrel pretreatment on major cardiac events.

Main Methods:

• A meta-analysis was conducted using data from MEDLINE, EMBASE, and Cochrane Controlled Trials Register.
• Included studies comprised 6 randomized controlled trials (RCTs), 2 observational analyses of RCTs, and 7 observational studies, totaling 37,814 patients.
• Quality assessment used the Ottawa Scale and Jadad Score; a random-effect model was applied for analysis.

Main Results:

• Clopidogrel pretreatment was not associated with a reduction in all-cause mortality (OR, 0.80; 95% CI, 0.57-1.11).
• A significant reduction in major cardiac events was observed with clopidogrel pretreatment (OR, 0.77; 95% CI, 0.66-0.89).
• No significant association was found between clopidogrel pretreatment and major bleeding (OR, 1.18; 95% CI, 0.93-1.50).

Conclusions:

• Clopidogrel pretreatment for patients undergoing PCI is not associated with reduced mortality.
• Clopidogrel pretreatment is associated with a lower risk of major coronary events in patients undergoing PCI.